Volume , Issues, ISSN: 1570-1603 (Online) ISSN: 1570-1603 (Print)
This journal supports open access
Aims & Scope
Current Pharmacogenomics and Personalized Medicine (CPPM) is a transdisciplinary, peer-reviewed,
biomedical journal that reports new findings and cutting-edge concepts in all areas of pharmacology.
Special consideration is given to articles on pharmacogenomics and personalized medicine. CPPM is an
accelerator for global personalized medicine and pharmacogenomics, as well as preclinical and clinical
pharmacology. Importantly, the journal provides a multi-disciplinary, integrated platform from cell to
society to address diagnostics and responsible pharmacogenomics applications in developing countries
and the entire range of translational science from bench-to-bedside in various therapeutic areas such as
oncology, cardiovascular, neuropharmacology, endocrine diseases, amongst others.
CPPM cooperates with the Ibero-American Network of Pharmacogenetics and the Pacific Rim
Association for Clinical Pharmacogenetics and welcomes peer reviewed contributions from authors in
any global region.
The journal's scope is defined by four inter-connected aims. First, we are interested in
genomics/postgenomics biotechnologies and diagnostics that enable global personalized medicine
science (including and beyond pharmacogenomics), as long as they explain person-to-person and
population differences in disease susceptibility or response to a health intervention, and can be
substantiated. Second, we approach personalized medicine as ‘personalized health interventions’
focusing primarily on drug therapy, but also other interventions such as nutrition, vaccines, surgical
devices, emerging cell-based therapies that collectively contribute to healthcare. Third, we strive to
integrate molecular and clinical investigation with public policy, global health diplomacy and social
studies of biotechnology, that collectively shape postgenomics future(s) and innovation trajectories in
life sciences. Fourth, we are interested in all aspects of translational pharmacology from preclinical to
clinical applications in any therapeutic area that will advance the practice of medicine for the benefit of
patients worldwide including non-communicable diseases as well as infectious diseases in the post-
Priority will be given to expert reviews/ mini-reviews and research articles that include original ideas and
findings related to the scope and mandate of the journal. Unsolicited submissions are welcomed.